GEODE CAPITAL MANAGEMENT, LLC has added 900,746 shares of $XENE to their portfolio, per a new SEC 13F filing. This disclosure reflects the funds' holdings for the 06-30-2025 report period. You can see the fund's full portfolio on Quiver Quantitative, and also track the largest institutional owners of $XENE.
XENON PHARMACEUTICALS Hedge Fund Activity
We have seen 86 institutional investors add shares of XENON PHARMACEUTICALS stock to their portfolio, and 100 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GEODE CAPITAL MANAGEMENT, LLC added 900,746 shares (+1294.2%) to their portfolio in Q2 2025, for an estimated $28,193,349
- DEEP TRACK CAPITAL, LP added 830,868 shares (+491.3%) to their portfolio in Q1 2025, for an estimated $27,875,621
- FMR LLC added 762,209 shares (+10.1%) to their portfolio in Q1 2025, for an estimated $25,572,111
- LOGOS GLOBAL MANAGEMENT LP added 650,000 shares (+inf%) to their portfolio in Q1 2025, for an estimated $21,807,500
- BAKER BROS. ADVISORS LP removed 646,271 shares (-65.0%) from their portfolio in Q1 2025, for an estimated $21,682,392
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 640,845 shares (-44.6%) from their portfolio in Q1 2025, for an estimated $21,500,349
- CAPITAL INTERNATIONAL INVESTORS added 541,520 shares (+21.3%) to their portfolio in Q1 2025, for an estimated $18,167,996
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
XENON PHARMACEUTICALS Insider Trading Activity
XENON PHARMACEUTICALS insiders have traded $XENE stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $XENE stock by insiders over the last 6 months:
- STEVEN GANNON sold 3 shares for an estimated $91
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
XENON PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $XENE in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Evercore ISI Group issued a "Outperform" rating on 05/14/2025
- Wells Fargo issued a "Overweight" rating on 05/13/2025
- RBC Capital issued a "Outperform" rating on 05/13/2025
- HC Wainwright & Co. issued a "Buy" rating on 05/13/2025
- Needham issued a "Buy" rating on 05/13/2025
- Chardan Capital issued a "Buy" rating on 05/13/2025
- Goldman Sachs issued a "Buy" rating on 04/17/2025
To track analyst ratings and price targets for XENON PHARMACEUTICALS, check out Quiver Quantitative's $XENE forecast page.
XENON PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $XENE recently. We have seen 8 analysts offer price targets for $XENE in the last 6 months, with a median target of $55.0.
Here are some recent targets:
- Cory Kasimov from Evercore ISI Group set a target price of $55.0 on 05/14/2025
- Mohit Bansal from Wells Fargo set a target price of $47.0 on 05/13/2025
- Brian Abrahams from RBC Capital set a target price of $55.0 on 05/13/2025
- Douglas Tsao from HC Wainwright & Co. set a target price of $53.0 on 05/13/2025
- Serge Belanger from Needham set a target price of $55.0 on 05/13/2025
- Rudy Li from Chardan Capital set a target price of $55.0 on 05/13/2025
- Paul Choi from Goldman Sachs set a target price of $52.0 on 04/17/2025
Note that there may be inaccuracies in these estimates due to filing errors by the funds, parsing errors by us, or other anomalies.
Check out Quiver Quantitative's $XENE ticker page for more data.
